

Alcohol Stimulation - Moderate Imputation

Author(s) and Year	Medication	Dose	DpM	BrAC	Hedge's G [95% CI]
Brasser et al., 2004	Acamprosate	4000	112.4	0.11	-0.40 [-1.42, 0.61]
Hammarberg et al., 2009	Acamprosate	1998	174.1	0.055	-0.07 [-0.62, 0.47]
Voronin et al., 2008	Aripiprazole	15	211.7	0.022	0.03 [-0.67, 0.72]
Kranzler et al., 2008	Aripiprazole	10	15.9	0.07	-0.58 [-1.07, -0.09]
Evans & Bisaga, 2009	Baclofen	80	120.9	0.09	-0.02 [-0.56, 0.52]
Leggio et al., 2013	Baclofen	30	237.6	0.03	1.72 [0.55, 2.89]
Covault et al., 2014	Dutasteride	4	34.7	0.073	-0.09 [-0.42, 0.24]
Pierucci-Lagha et al., 2005	Finasteride	100	11.1	0.06	-0.26 [-0.99, 0.48]
Bisaga & Evans, 2006	Gabapentin	2000	147	0.09	0.01 [-0.59, 0.61]
Myrick et al., 2007	Gabapentin	1200	177.8	0.021	-0.10 [-0.75, 0.54]
Ray et al., NA	Idbudilast	100	138.8	0.08	0.05 [-0.23, 0.32]
Haass-Koffler et al., 2015	Idazoxan	40	40.1	0.06	-0.59 [-1.28, 0.11]
Pickworth et al., 1997	Indomethacin	58.74	51.4	0.115	-0.40 [-1.54, 0.73]
Penetar et al., 2011	Isoflavone	750	33.4	0.11	-0.37 [-1.43, 0.68]
Roche et al., 2016	Ivermectin	30	168.3	0.08	-0.05 [-0.48, 0.38]
Chi and de Wit, 2003	Mecamylamine	15	32.4	0.08	-0.26 [-0.91, 0.40]
Young et al., 2005	Mecamylamine	15	36.4	0.02	-0.33 [-0.87, 0.21]
Bisaga & Evans, 2003	Memantine	30	87.9	0.1	-0.28 [-0.97, 0.40]
Drobes et al., 2004	Nalmefene	50	186.8	0.055	-0.10 [-0.55, 0.35]
Drobes et al., 2004	Nalmefene	50	17.8	0.055	-0.42 [-0.94, 0.11]
Anton et al., 2004	Naltrexone	50	160	0.03	-0.23 [-1.07, 0.62]
Anton et al., 2012	Naltrexone	50	174.9	0.025	-0.23 [-0.66, 0.20]
Drobes et al., 2004	Naltrexone	50	186.8	0.055	-0.20 [-0.62, 0.23]
Drobes et al., 2004	Naltrexone	50	17.8	0.055	-0.10 [-0.61, 0.41]
King et al., 1997	Naltrexone	50	39.1	0.06	0.13 [-0.59, 0.85]
King et al., 1997	Naltrexone	50	44.6	0.06	-0.37 [-1.07, 0.33]
King et al., 1997	Naltrexone	50	41.7	0.06	-0.40 [-0.72, -0.07]
Na and Lee, 2002	Naltrexone	50	19	0.074	-0.28 [-0.65, 0.10]
Peterson et al., 2006	Naltrexone	50	40.1	0.07	-0.29 [-1.05, 0.46]
Plebani et al., 2011	Naltrexone	50	14.1	0.056	0.04 [-0.17, 0.25]
Ray et al., 2012	Naltrexone	50	48.4	0.06	-0.04 [-0.27, 0.20]
Ray et al., 2014	Naltrexone	25	135.4	0.067	-0.05 [-0.48, 0.38]
Ray et al., 2007	Naltrexone	50	44	0.06	-0.44 [-0.67, -0.21]
Ray et al., 2008	Naltrexone	50	41.7	0.033	-0.52 [-0.76, -0.28]
Setiawan et al., 2011	Naltrexone	50	66.4	0.01	-0.06 [-0.26, 0.14]
Swift et al., 1994	Naltrexone	50	17.9	0.05	-0.51 [-0.92, -0.10]
Doty et al., 1997	Naltrexone	50	39	0.025	-0.27 [-0.92, 0.39]
de Wit et al., 1999	Naltrexone	50	34.3	0.09	-0.41 [-0.95, 0.13]
Hutchison et al., 2001	Olanzapine	5	100.9	0.06	-0.26 [-1.01, 0.49]
Hutchison et al., 2003	Olanzapine	5	43.5	0.06	-0.16 [-0.64, 0.31]
Swift et al., 1996	Ondansetron	8	5.6	0.05	0.92 [0.25, 1.59]
McCloskey et al., 2009	Paroxetine	20	40.1	0.1	-0.19 [-0.73, 0.35]
Ray et al., 2011	Quetiapine	400	138.9	0.06	0.10 [-0.87, 1.07]
George et al., 2010	Rimonabant	20	153.3	0.03	-0.21 [-0.83, 0.40]
Estevez et al., 1995	Ritanserin	10	40.1	0.055	-0.25 [-0.77, 0.28]
Miranda et al., 2008	Topiramate	300	122.4	0.08	-0.47 [-0.93, -0.01]
Childs et al., 2012	Varenicline	2	69.4	0.09	0.12 [-0.23, 0.47]
McKee et al., 2009	Varenicline	2	128.3	0.021	-0.91 [-1.70, -0.12]
Ray et al., 2014	Varenicline	2	135.4	0.067	0.47 [0.04, 0.91]
Sarid-Segal et al., 2009	Zonisamide	100	102	0.03	-0.40 [-1.54, 0.73]

